logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10392404 B1

PDFFull Text
Date of Patent:
Aug. 27, 2019

Filed:

Sep. 11, 2015

Compounds and compositions as kinase inhibitors

Applicant:

Novartis Ag, Basel, CH;

Inventors:

Paul Andrew Barsanti, Pleasant Hill, CA (US);

Matthew T. Burger, Belmont, MA (US);

Yan Lou, Pleasanton, CA (US);

Gisele A. Nishiguchi, Arlington, MA (US);

Valery Rostislavovich Polyakov, Morage, CA (US);

Savithri Ramurthy, Emeryville, CA (US);

Sharadha Subramanian, San Ramon, CA (US);

Benjamin R. Taft, Oakland, CA (US);

Huw Rowland Tanner, San Francisco, CA (US);

Lifeng Wan, Union City, CA (US);

Assignee:

Novartis AG, Basel, CH;

Attorney:

Scott W. Reid

Primary Examiner:

Andrew D Kosar

Assistant Examiner:

John S Kenyon

Int. Cl.
CPC ...
A61K 31/444 (2006.01); C07D 498/08 (2006.01); C07D 401/14 (2006.01); C07D 413/14 (2006.01); C07D 213/74 (2006.01); C07D 401/04 (2006.01); C07D 401/10 (2006.01); C07D 407/14 (2006.01); C07D 411/14 (2006.01); C07D 413/12 (2006.01); A61K 31/4418 (2006.01); A61K 31/496 (2006.01); A61K 31/501 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); C07D 213/85 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 451/02 (2006.01);
U.S. Cl.
CPC ...
C07D 498/08 (2013.01); A61K 31/444 (2013.01); A61K 31/4418 (2013.01); A61K 31/496 (2013.01); A61K 31/501 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); C07D 213/74 (2013.01); C07D 213/85 (2013.01); C07D 401/04 (2013.01); C07D 401/10 (2013.01); C07D 401/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 407/14 (2013.01); C07D 411/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 451/02 (2013.01);
Abstract

The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

Find Patent Forward Citations

Loading…